The X-ray images (from: Journal of the IABC, Vol. 1, January-December, 2002), for a 52 year old lung cancer patient show a 9.5 cm. by 11.0 cm. carcinoma (left photo), diagnosed by needle biopsy. The patient was not a candidate for surgery, chemotherapy or radiation therapy because of a chronic obstruction, pulmonary disease and coronary heart disease. Six platinum EChT electrodes were inserted into the skin and into the tumor mass using X-ray monitoring. After the patient received six months of EChT treatment, the tumor completely disappeared (right photo). The patients progress has been very good. He has had a check up every year. Follow-up has been on-going for 10 years.
One of the primary medical missions of the IABC is to advise and assist scientists, medical doctors and investors in their efforts to develop and promote lower cost, patient friendly and less harmful therapeutic alternatives for a variety of health problems. One of our biggest concerns involves the unquestioned approval and proliferation of harmful therapeutic modalities that have been promoted for so many years, and have been proven to be dangerous or deadly for the patients who have trusted the advice of their doctors. Recent revelations concerning the misuse and dangers of hormone replacement therapy, bypass surgery and a host of dangerous drugs for the treatment of depression are strong indicators that allopathic medicine needs to review the words and meaning of the Hippocratic Oath and the Declaration of Helsinki.
A number of different opinions and interpretations of the Hippocratic Oath can be found at the following website: www.pbs.org/wgbh/nova/doctors/oath_classical.html The Declaration of Helsinki can be found at the following website: http://ohsr.od.nih.gov/guidelines/helsinki.html or www.cirp.org/library/ethics/helsinki/ .
Another component of the IABC medical mission is to assist those who are working to improve the models and dogma of physiology and medicine, and to promote research activities in complementary therapeutic techniques. We hope that our efforts will contribute to a better understanding of how the body heals and regulates itself, to promote and develop better therapeutic alternatives that are more compatible with the natural physical processes that occur in the human body, to promote and provide more effective complementary therapeutic alternatives and to assist in the development of therapeutic alternatives that are more reasonable and realistic with respect to cost and treatment protocol.
The history of the research efforts in electrotherapy and the bioelectric properties of living systems, leading up to EChT, is very interesting. The application of direct current to needle electrodes (galvanopuncture) has been used to treat aneurysms as early as 1849. Techniques to destroy malignant tumors with localized high frequency alternating current spark techniques were under investigation in the early 1900's. The precursors to Dr. Nordentström's EChT technique have a 150 year history. The application of electrotherapy to various health problems has a significant amount of scientific credibility, with over 150 years of experimental validation, published in various medical journals, hospital reports and books.
EChT techniques have been used to treat over 12,000 cancer patients, with localized tumors, in a number of countries (including Australia, China, Cuba, Germany, Sweden and a "very limited" group of studies in the U.S.) for more than 25 years. Compared with conventional cancer therapies, EChT's therapeutic efficacy is impressive (see Clinical Trials), especially when one considers that most of the cancer patients treated with EChT are in the stage II and stage III categories.
A very limited number of U.S. cancer patients were given permission to be treated with EChT in several FDA monitored clinical trials (including Washington University Medical School, St. Louis, MO and City of Hope, Duarte, CA). However, only patients who had exhausted all conventional alternatives were allowed to be treated with EChT in these clinical trials. Many of the cancer patients showed positive responses to EChT treatment. However, with the type of constraints imposed by the FDA study rules, the patients' cardiovascular health and immune systems were so seriously compromised by conventional approaches, that they died of complications from previous therapy not long after starting the EChT treatment protocol.
If the welfare of cancer patients is of some concern, and if the Hippocratic Oath is to be taken seriously, the questions must be asked; "Why does a U.S. cancer patient, with a localized tumor, have to travel outside the U.S. to receive EChT treatment? Why is EChT not available in the U.S.?"
From: J.E. Petrequin, Bull. Gen. de Therap., October, 1849; E. Doyen, Arch. Med. et de Physiol., Vol. 17, 1909; S. Ingvar, Soc. Exper. Biol. Med. Proc., Vol. 17, 1919-1920; D. Ingvar, Acta. Physiol. Scandinav., Vol. 13, 1947; A. Szent-Györgyi, Bioenergetics, Academic Press, New York (1957); G.D. O'Clock, Proceedings of the Fourth International Symposium on Biologically Closed Electric Circuits, October 26-29, 1997; Y.L. Xin, The European Journal of Surgery, Supplement 574, 1994, Y.L Xin, Bioelectromagnetics, Vol. 18, 1997, G.D. O'Clock, German Journal of Oncology, Vol. 33, 2001, Y.L. Xin, Journal of the IABC, Vol. 1, January-December, 2002 and G.D. O'Clock, Journal of the IABC, Vol. 1, January-December, 2002.